Form 10-Q · Quarterly report
West Pharmaceutical Services 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0000105770
- Accession no.
- 0000105770-26-000121
Summary
West Pharmaceutical Services reported third-quarter 2026 GAAP net income of $214.0 million, or $3.02 per diluted share, and adjusted net income of $188.8 million, or $2.66 per diluted share, compared with GAAP net income of $140.0 million, or $1.92 per diluted share, a year earlier. The company also agreed to sell its SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie, recording a net gain of $55.7 million, and said it does not expect recent U.S. tariff refunds or the Middle East conflict to have a material impact on its 2026 results.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION OVERVIEW The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2025 Annual Report. Our historical financial statements may not be indicative of our future performance. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.